ReviewEuropean journal of nuclear medicine and molecular imaging2014
Current role of FDG PET/CT in lymphoma.
Review in European journal of nuclear medicine and molecular imaging, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 74 citations in OpenAlex.
- US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2016Trial
- Assessing PET-CT versus conventional CT: a meta-analysis on diagnostic efficacy, prognosis, and post-surgical wound healing in lung mucosal marginal zone lymphoma.Frontiers in oncology · 2026Article
- Clinical applications of artificial intelligence in the histopathology of lymphoma: diagnosis, treatment and prognosis.Discover oncology · 2025Review
- Prognostic Value of FDG PET/CT in Patients with Nodal Peripheral T-Cell Lymphoma.Diagnostics (Basel, Switzerland) · 2023Article
- Deep Learning-Based Segmentation and Volume Calculation of Pediatric Lymphoma on Contrast-Enhanced Computed Tomographies.Journal of personalized medicine · 2023Article
- Article
- Comparison of FDG PET/CT and Bone Marrow Biopsy Results in Patients with Diffuse Large B Cell Lymphoma with Subgroup Analysis of PET Radiomics.Diagnostics (Basel, Switzerland) · 2022Article
- Quantitative Whole-Body Diffusion-weighted MRI after One Treatment Cycle for Aggressive Non-Hodgkin Lymphoma Is an Independent Prognostic Factor of Outcome.Radiology. Imaging cancer · 2021Article
- Article
- A Survey Exploring Personalised Medicine amongst Radiography Academics within the United Kingdom.Journal of medical imaging and radiation sciences · 2020Article
- Article
- Prognostic Value of Functional Parameters ofContrast media & molecular imaging · 2019Article
- Ultra-early response assessment in lymphoma treatment: [European journal of nuclear medicine and molecular imaging · 2018Article
- Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography with gallium-67 scintigraphy in the initial clinical staging of diffuse large B-cell lymphoma.International journal of hematology · 2018Article
- Response assessment with the CXCR4-directed positron emission tomography tracer [EJNMMI research · 2017Article
- CT-based texture analysis potentially provides prognostic information complementary to interim fdg-pet for patients with hodgkin's and aggressive non-hodgkin's lymphomas.European radiology · 2017Article
- A novel non-Hodgkin lymphoma murine model closer to the standard clinical scenario.Journal of translational medicine · 2016Article
- The Strategies to Homogenize PET/CT Metrics: The Case of Onco-Haematological Clinical Trials.Biomedicines · 2016Review
- FDG PET/CT response in diffuse large B-cell lymphoma: Reader variability and association with clinical outcome.Medicine · 2016Observational
- 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.Investigative radiology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The management approach in Hodgkin's (HL) and high-grade non-Hodgkin's lymphomas (NHL) has shifted towards reducing the toxicity and long-term adverse effects associated with treatment while maintaining favorable outcomes in low-risk patients. The success of an individualized treatment strategy depends largely on accurate diagnostic tests both at staging and during therapy. In this regard, positron emission tomography (PET) using fluorodeoxyglucose (FDG) with computed tomography (CT) has proved effective as a metabolic imaging tool with compelling evidence supporting its superiority over conventional modalities, particularly in staging and early evaluation of response. Eventually, this modality was integrated into the routine staging and restaging algorithm of lymphomas. This review will summarize the data on the proven and potential utility of PET/CT imaging for staging, response assessment, and restaging, describing current limitations of this imaging modality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.